Corbus Pharmaceuticals (NASDAQ:CRBP – Get Free Report) is expected to release its Q3 2026 results before the market opens on Wednesday, November 11th. Analysts expect Corbus Pharmaceuticals to announce earnings of ($1.27) per share and revenue of $1.67 million for the quarter. Interested persons can check the company’s upcoming Q3 2026 earnings report for the latest details on the call scheduled for Friday, November 20, 2026 at 12:30 PM ET.
Corbus Pharmaceuticals Stock Performance
CRBP stock opened at $3.52 on Tuesday. The business has a 50 day moving average price of $6.28 and a 200 day moving average price of $8.45. Corbus Pharmaceuticals has a fifty-two week low of $2.81 and a fifty-two week high of $12.88.
Insider Activity
In other news, major shareholder Cormorant Asset Management, Lp sold 425,000 shares of the firm’s stock in a transaction that occurred on Thursday, October 29th. The shares were sold at an average price of $4.10, for a total transaction of $1,742,500.00. Following the transaction, the insider directly owned 1,919,971 shares in the company, valued at approximately $7,871,881.10. This trade represents a 18.12% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Company insiders own 3.50% of the company’s stock.
Analyst Ratings Changes
View Our Latest Analysis on CRBP
About Corbus Pharmaceuticals
Corbus Pharmaceuticals Holdings, Inc is a biopharmaceutical company focused on developing medicines for serious diseases in oncology and immunology. The company’s research is centered on therapies designed to modulate immune-cell activity and target biological pathways involved in cancer and inflammatory disease.
Corbus’ oncology pipeline has included soquelitinib, formerly known as CPI-818, an oral, selective inhibitor of interleukin-2-inducible T-cell kinase (ITK) being evaluated for its potential to treat T-cell lymphomas and other cancers.
Featured Stories
- Five stocks we like better than Corbus Pharmaceuticals
- Wall Street May Be Making a Big Mistake With monday.com Stock
- Are These 2 Mid-Cap Growth Stocks Worth the Risk?
- Oklo Changes the Narrative: Does a Nuclear Stock Price Explosion Come Next?
- Cloudflare’s 20% Sell-Off May Have Created an Opening for Investors
Receive News & Ratings for Corbus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Corbus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
